BETA BIONICS INC

BBNXNASDAQ

🏆 #2212 by market capEarnings Oct 27US Equity

$17.62▲ $1.31 (+7.44%)

🌙 After hours$17.28▼ 1.91%Regular close · extended-hours price shown

1h—

24h▲ 7.4%

7d▲ 26.5%

14d▲ 16.4%

30d▲ 3.8%

1y▲ 24.0%

🏦Market Cap

$793M

Small Cap

📈Revenue Growth (YoY)

+94.1%

High Growth

📊Gross Margin

58.3%

Healthy

💵FCF Margin

—

⚖️P/S Ratio

6.2x

Fair

Otter Score

Weak

Trading Snapshot

Day Range: $17.47 – $17.72
52-Week Range: $8.80 – $32.71
Volume: $4.53B
Avg Volume: $4.85B
Shares Outstanding: 45.0M
Next Earnings: Sep 10, 2026

Fundamentals Snapshot

Annual Revenue: $100M
Last Q Revenue: $32M
P/E Ratio: —
P/S Ratio: 6.2x
EPS (TTM): $-1.65
Dividend Yield: —

Why Investors Own BBNX

✓High-growth profile — revenue up +16.8% YoY with expanding US Equity exposure.
✓Healthy economics — 54% gross margin and 7% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.

⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

Financial Trends

Revenue (TTM)

$100M▲ +21.9% YoY

Gross Margin (TTM)

54.2%▲ +2.4% YoY

Operating Income (TTM)

$20M▲ +21.9% YoY

Free Cash Flow (TTM)

$7M▲ +21.9% YoY

About BETA BIONICS INC

Beta Bionics, Inc. is a commercial-stage medical technology company dedicated to inventing, developing, and bringing to market solutions that improve the health and quality of life for individuals with diabetes who depend on insulin. The company's flagship product, the iLet Bionic Pancreas, is an automated insulin delivery system currently available for treating type 1 diabetes in adults and children aged six and older. In addition to its existing offering, Beta Bionics is actively developing several new innovations: a Patch Pump, designed as a tubeless insulin pump that adheres directly to the skin; the Bihormonal iLet, which integrates automated delivery of both insulin and glucagon; and an iLet system specifically adapted for individuals with insulin-dependent type 2 diabetes. To support its product pipeline, the company has forged strategic alliances, including a collaboration and licensing agreement with Xeris Pharmaceuticals, Inc. to develop and commercialize a glucagon formulation compatible with pumps. It also holds a development and commercialization agreement with Abbott Diabetes Care Inc. for an automated insulin delivery system. Established in 2015, Beta Bionics is headquartered in Irvine, California.

🦦